Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

3H-labeled transferrin substate, to study Arg-Gly-Asp (RGD) peptide, IL-1, chondrocytes, matrix metalloproteinase synthesis and, 1304
3H-thymidine
chondrocytes in aging and development and, 960
incorporation assay, to study CD28 cells in RA, 649
Hand
in acanthosis nigricans, 862
bone mineral density in RA, 1204
bullous rash, brown urine and, after hydroxychloroquine in SLE, 440
clenched fist syndrome, 57
exacerbation of cutaneous LE from ultraviolet emission from a photocopier, 1152
guidelines for medical management of OA and, 1541
joint space measurement of, using computers, 891
in juvenile AS and JRA, 835
Haplotypes, DQB1*0302, DRB1*0401, MHC class II genes, anti-U1 snRNP antibodies and, 396
Hardy-Weinberg equilibrium, shared-epitope DRB1 alleles, RA gene and, 1754
Head injury, cognitive deficit in rheumatic diseases and, 1363
Headache, CAMPATH-1H in RA and, 1187, 1589
Health Assessment Questionnaire
functional disability in PM/DM and, 1218
in RA, 49, 1204, 1568
in Spanish outcome measures, 1429
Health care, practice guidelines and, 1533
Health care reform, student's perspective on RA and, 315
Health care utilization
impact of musculoskeletal conditions and, 1351
sexual abuse in fibromyalgia and, 161, 229, 235
Health insurance, access to medical care for musculoskeletal conditions and, 1128
Health maintenance organizations, incidence of OA in, 1134
Health outcomes, long-term, evaluative laboratory testing and, 1555
Health status in RA
stress management and, 1807
work disability and, 1630
Heart disease, coronary, cardiovascular fitness in end-stage OA and, 799
Heat, Raynaud's phenomenon, scleroderma and, 1
Heat-killed mycobacteria, to study substance P and calcitonin gene-related petide in rat adjuvant arthritis, 699
Heat-shock protein 60
Lyme borreliosis and, 565
pathogenesis of spondylarthropathies and, 1547
Heat-shock protein 65, T cell receptors in RA and, 577
Heavy chains
human monoclonal antiphospholipid antibody and, 1068
IgG receptors in autoimmune disease and, 306
immunoglobulin, in anti-DNA antibody binding, 389
Height, factors affecting bone mass and, 61
Height, hand bone mineral density in RA and, 1204
HeLa cells
Chlamydia trachomatis in synovial membrane and, 1410
Mi-2 autoantigen in DM and, 123
Sm antigen, MHC class II genes, anti-U1 snRNP antibody and, 396
Helicase, Mi-2 autoantigen in DM and, 1389
Helicobacter pylori infection, NSAID, gastrointestinal tract and, 5
Helper cells
autoimmune disease induction by microbial pathogens and, 458
in RA, 384, 1701
Hemagglutination, to study MHC class II genes and anti-U1 snRNP antibody, 396
Hemangioma, localized synovial, 559
Hematocrit, erythrocytes in rheumatoid vasculitis and, 248
Hematologic abnormalities
parvovirus B19 infection, chronic fatigue syndrome and, 638
in SLE, 1475
Hematology
of Felty's syndrome and large granular lymphocyte syndrome, 1252
macrophages, clodronate-containing liposomes and, in rat adjuvant arthritis, 1777
somatostatin in experimental arthritis and, 1687
toxicities, cost of drugs in RA and, 318
Hematopoietic cells, immunosuppressive drugs during pregnancy and, 1722
Hematoxylin and eosin staining, to study cutaneous PAN associated with Crohn's disease and atrial myxoma, 1161
Hematuria
in C4 deficiency in glomerulonephritis, 1333
renal biopsy in RA and, 242
Hemithalamus, cerebral blood flow and pain in fibromyalgia and, 926
Hemoceles, Lyme borreliosis and, 565
Hemochromatosis, iron salute as sign of, 558
Hemocyanin, keyhole limpet, antigen-induced arthritis type II collagen and, 1092
Hemoglobin
cytokines in JRA and, 211, 1531
in pseudoseptic inflammatory knee effusion in sickle cell disease, 284
Hemolytic disease of the newborn, immunosuppressive drugs during pregnancy and, 1722
Hemorrhage
antineutrophil cytoplasmic antibody-negative pulmonary capillaritis, circulating primed neutrophils and, 1855
in cutaneous PAN associated with Crohn's disease and atrial myxoma, 1161
gastrointestinal, with Chinese herbal medications plus prescription drugs, 614
subepithelial, NSAID, gastrointestinal tract and, 5
HEp-2 cell protein, Mi-2 autoantigen in DM and, 1389
Heparin-induced thrombocytopenia, antibody-mediated, IgG receptors in autoimmune disease and, 306
Hepatic involvement, liver biopsy after long-term MTX in RA and, 1194
Hepatic toxicity, heterozygous α1-antitrypsin deficiency, end-stage renal disease after MTX and, 1014
Hepatitis, serum, autoimmunity and, 301, 1532
Hepatitis B
corticosteroids, pulse cyclophosphamide and plasma exchange in polyarteritis nodosa and Churg-Strauss syndrome, 1638
infection, autoimmunity and, 301, 1532
Hepatitis C, PM, pulmonary fibrosis and, 437
Hepatotoxicity, ACR recommendations for liver biopsy in RA after MTX and, 1115
Heterogeneous nRNP, autoimmune response to the spliceosome and, 777
Heteropolymers, antigen-based, 190
Heterozygous α1-antitrypsin deficiency, end-stage renal disease after MTX and, 1014
High-density lipoprotein, anti-apolipoprotein A1 in SLE and, 1655
High-dose fish oil, NSAID in RA and, 1107
High-frequency sonography, to study finger tendons in RA, 786
High performance liquid chromatography
gel-permeation, to study TGFβ1 in hyaluronan synthesis in synovial lining cells, 669
reverse-phase, to study substance P and calcitonin gene-related peptide in rat adjuvant arthritis, 699
to study antiinflammatory mechanism of adenosine regulators, 1040
to study elastin and collagen degradation in SSc, 517
Hip
flexion, in walking velocity in elderly, 343
fracture, infection, onset of giant cell arteritis and, 374
joint, loosening of revision total replacement of, 1315
osteophytes, 907
prosthesis, in RA, 334, 1315
Hip OA
bone mineral density in, 907
end-stage, cardiovascular fitness and health in, 799
guidelines for medical management of, 1535
Hispanic patients
geographic clusters of SLE, 1564
HLA-DR5 (DRB1*1201), in primary antiphospholipid syndrome in Mexican patients, 1340
Spanish outcome measures, 1429
Histidine, MHC class II genes, anti-U1 snRNP antibody and, 396
Histochemistry, to study monoclonal antibodies in detection of biochemical markers of arthritis, 655
Histology
in carpal tunnel syndrome due to T cell lymphomas, 1707
HIV infection, progressive joint destruction and, in RA, 1328
in IL-1 in experimental arthritis in mice, 164
MTX and, 1014, 1115
in OA, 201, 1290
in quantification of rheumatoid synovitis by MRI, 1610
radiographic changes in adjuvant arthritis in rats and, 129
in sacroiliitis in AS, 499
scleroderma in Tsk2 mouse and, 1791
somatostatin in experimental arthritis and, 1687
in spinal involvement in gout, 139
stromelysin degradation of cartilage and, 173, 1678
Histone-like protein, pathogenesis of spondylarthropathies and, 1547
Histones, nucleosome-restricted antibodies in SLE and, 1485
Histopathology
biopsy and, in RA, 242, 1194
exacerbation of cutaneous LE from ultraviolet emissions from a photocopier, 1152
in scleroderma in Tsk2 mouse and, 1791
somatostatin in experimental arthritis and, 1687
HLA
alleles, 259, 1660
antigens, 547, 845
anti-U1 RNA antibodies in connective tissue disease and, 1837
class II genes, 396, 684, 1660
class II molecules, 1715
DNA typing, gold-induced enterocolitis, HLA-DRB1*0404 allele and, 755
genes, 1715
macrophages, clodronate-containing liposomes and, in rat adjuvant arthritis, 1777
MHC class II genes, anti-U1 snRNP antibody and, 396
polymorphism, 1715, 1837
T cell receptors in RA and, 577
TAP alleles, Reiter's syndrome and, 684
type, 259, 577
typing, 845, 1672
HLA-B27
in AS, 381, 547, 1277, 1672
autoimmune disease induction by microbial pathogens and, 458
occurrence of AS in twins in Finland and, 381
pathogenesis of spondylarthropathies and, 1547
in pauciarticular JRA, 1672
TAP alleles, Reiter's syndrome and, 684
HLA-B39
in AS and pauciarticular JRA, 1672
HLA antigens, disease progression and, in psoriatic arthritis, 845
HLA-B51,transgenic mice, peripheral blood neutrophils in Behcet's disease and, 426
HLA-DQ, HLA type in MCTD and, 259
HLA-DQA genes, HLA-DQB genes, HRES-1 antibodies and, in SLE and overlap syndromes, 1660
HLA-DQB1 gene, anti-U1 snRNP antibody and, 396
HLA-DR
antigen, CD28 cells in RA and, 649
polyglot, polymorphism and, 1715
HLA-DR2/DR4, anti-U1 RNA antibodies in connective tissue disease and, 1837
HLA-DR5 (DRB1*1201), in primary antiphospholipid syndrome in Mexican patients, 1340
HLA-DR7, HLA antigens, disease progression and, in psoriatic arthritis, 845
HLA-DR8, in acute anterior uveitis in AS, 547
HLA-DRB genes, HRES-1 antibodies and, in SLE and overlap syndromes, 1660
HLA-DRB1 alleles, HLA-DR8, acute anterior uveitis and, in AS, 547
HLA-Dw4, in RA, 298
Hodgkin's lymphoma, Epstein-Barr associated, in RA after MTX and cyclosporine, 867
Homebound elderly, walking velocity in, 343
Homeostasis, T cell receptors, RA and, 1242
Homology
anti-apolipoprotein A1 in SLE and, 1655
human monoclonal antiphospholipid antibody and, 1068
polyglot, polymorphism and, 1715
Hormones
cytokines, early response genes and, 877
growth, insulin-like growth factor 1 in OA and, 413
luteinizing releasing hormone agonist, leuprolide, immunosuppressive drugs during pregnancy and, 1722
replacement therapy with, in postmenopausal RA bone metabolism, 902
Hospitalization
cost of drugs in RA and, 318
epidemiology of SLE and, 1260
impact of musculoskeletal conditions and, 1351
joint and connective tissue ultrasonography and, 736
NSAID-induced gastroduodenal injury in children, 1225
prevalence and incidence of SLE in Birmingham, England and, 551
in pseudoseptic inflammatory knee effusion in sickle cell disease, 284
HRES-1 antibodies, in SLE and overlap syndromes, 1660
HTLV gp46 envelope protein, HTLV-1 in PM and, 690
Human immunodeficiency virus (HIV)
autoimmune disease induction by microbial pathogens and, 458
HRES-1 antibodies, in SLE and overlap syndromes, 1660
infection, 1328, 1701, 1733
Human studies
anti-apolipoprotein A1 in SLE and, 1655
antigen-based heteropolymers, 190
antigen-induced arthritis, type II collagen and, 1092
antineutrophil cytoplasmic antibodies in mice and, 1375
autoimmune disease induction by microbial pathogens and, 458
bone marrow transplantation in antiphospholipid syndrome in mice and, 115
cartilage, 173, 1678, 1694
chondrocytes in aging and development, 960
IgG receptors in autoimmune disease, 306
IL-1 in experimental arthritis in mice and, 164
IL-1α polymorphism in JRA, 221
immunoglobulin heavy chain in anti-DNA antibody binding, 389
immunosuppressive drugs during pregnancy, 1722
Human studies (cont'd)
insulin-like growth factor 1 in OA, 413
Lyme borreliosis, 565
Mi-2 autoantigen in DM and, 1389
monoclonal antibodies, 655, 1187
monoclonal antiphospholipid antibody, 1068
nitric oxide and lipoxin A4 polymorphonuclear neutrophil vascular cytotoxicity, 768
peripheral blood neutrophils in Behcet's disease, 426
protein, 1655
Ro and La antigens in human skin, 1271
TGFβ1 in hyaluronan synthesis in synovial lining cells, 669
Human T cell leukemia virus (HTLV), autoimmune disease induction by microbial pathogens and, 458
Human T cell leukemia/lymphoma virus-1 (HTLV-1), in PM, 690
Humanized monoclonal antibody, CAMPATH-1H, in RA, 1589
Hyaluronan synthesis, TGFβ1 in, in human synovial lining cells, 669
Hyaluronic acid
disease progression in OA and, 760
stromelysin-cleaved rabbit aggrecan and, 1400
Hybridization
dot-blot, 1754
in situ, 477, 492, 499, 678, 750, 1389
liquid, to study HTLV-1 in PM, 690
in RA, 1242, 1754
semiquantitative, 1242
Hybridomas, DNA binding of IgM[gl] anti-DNA antibody and, 389
Hydatid disease, in chronic monarthritis, 1339
Hydraulic permeability, stromelysin degradation of cartilage and, 1678
Hydrophobic amino acids, T cell receptors in RA and, 577
Hydroxychloroquine
bullous rash and brown urine after, in SLE, 440
pain and, 445
in RA, 318, 1447
Hydroxylysylpyridinoline, elastin and collagen degradation in SSc and, 517
Hydroxyproline, tiludronate, etidronate and, in Paget's disease of bone, 851
Hypermetabolic activity, proteoglycan synthesis in experimental OA and, 525
Hyperostosis, diffuse idiopathic skeletal, tracheal stenosis secondary to, 296, 1345
Hypersensitivity, delayed-type, antigen-induced arthritis, type II collagen and, 1092
Hypertension
CAMPATH-1H in active refractory RA and, 1187
diltiazem in calcinosis and, 1646
pulmonary, in fatal pulmonary vasculitis in lupus pregnancy, 710
racial factors in gout and, 628
Hypervariable region, polyglot, polymorphism and, 1715
Hypotension, CAMPATH-1H in RA and, 1589
Hypothalamic-pituitary-adrenal axis
dysregulation of, mud-baths and, 724
NSAID and, 723
Hypothalamus, IL-1 receptor antagonist in RA and, 642
Hypouricemia, in gouty arthritis in AIDS, 570
Hypoxanthine/xanthine oxidase system, nitric oxide and lipoxin A4 polymorphonuclear neutrophil vascular cytotoxicity and, 768